Pinned Tweet
It's hard to believe it's been almost a year! I'm still incredibly grateful for the opportunity to speak at ACG 2025 last year. Thank you for such a memorable experience! 'Screening, surveillance for MASLD needs to expand ‘beyond BMI’ healio.com/news/gastroentero…
@AASLDtweets @AASLDFoundation @AGA_GHAdvances @AmCollegeGastro @HealioGastro
Mapouka Mexan MD, MPH retweeted
❗ Pooled analysis data at #ACG2026 indicates that for people with #HIV, a third dose of the HepB-CpG vaccine is “worth considering” when “durable, high-level protection is the goal.”
@GoHealio spoke with @MapoukaMexan @UMCapRegionIM about that data 👇
vist.ly/5ndzy
Grateful to share this talk on hepB vaccine:
Third dose of HepB-CpG ‘worth considering’ to boost protection for people with HIV #ACG2026
healio.com/news/gastroentero…
@NkengehNTD
@SarpB44
@TashaRWilson
@AmCollegeGastro
@blackingastro
@AAFG_2021
Mapouka Mexan MD, MPH retweeted
💉 For patients with #HIV who did not respond to prior #HBV vaccination, three-dose HepB-CpG may be preferable.
🗨️ “HepB-CpG is the preferred revaccination choice over the old alum vaccines,” @MapoukaMexan @UMCapRegionIm told @GoHealio at #ACG2026 vist.ly/5na4q
Genome sequencing in MASLD 🔥
Feeling grateful! 🙏🏾
#ACG2026
@AmCollegeGastro
@UMCapRegionIM
@YaleIMed
@SarpB44
@HealioGastro
Feeling grateful to join the group for a morning run in Nashville before today’s ACG sessions! Always a great way to start the day! 🏃🏾♂️
Thank you to everyone who showed up!
@AmCollegeGastro
#DiversityinGIFUnRun
#GITweet
Mapouka Mexan MD, MPH retweeted
There’s no better place to be right now than Nashville, surrounded by our amazing #AAFG community!
Our members are ready to shine, with multiple posters, oral presentations, and lectures to share at #ACG2026
#GItwitter @POHER_NGO
I’m grateful and excited to present my work at the ACG on 10/12/2026! Please stop by posters P4073 and P3163 Exhibit Halls A - D (Level 3)
@AmCollegeGastro @HealioGastro
4
204
Grateful to share this paper on intersection depression/MASLD:
- Among U.S. adults with ACLD:
➡️ ~1 in 7 had comorbid depression
➡️ Women & young adults are particularly vulnerable
sciencedirect.com/science/ar…
@AASLDtweets @AmerGastroAssn @AGA_GHAdvances @AmCollegeGastro
Mapouka Mexan MD, MPH retweeted
🧠 Sometimes, the most meaningful research questions begin with one patient.
A patient with MASLD + unrecognized depression struggling with treatment made me ask: How much depression are we missing in ACLD?
That question became a national study now published in @AGA_GHAdvances.
Among U.S. adults with ACLD:
➡️ ~1 in 7 had comorbid depression
➡️ Burden increased after the COVID-19 pandemic
➡️ Women & young adults particularly vulnerable
Liver care cannot stop at the liver.
📄 doi.org/10.1016/j.gastha.202…
#Hepatology #MentalHealth #LiverDisease
Mapouka Mexan MD, MPH retweeted
Check out the September issue of GIE: giejournal.org/current
#GITwitter
Mapouka Mexan MD, MPH retweeted
🚨 Obesity is reshaping liver transplantation.
Our latest study analyzed ~180,000 liver transplant recipients across 3 decades using the @UNOSNews transplant registry.
📆 1988–2022
📈 Mean BMI: 24.7 → 28.9 kg/m²
🔮 Projected BMI by 2050: 30.1 kg/m²
Big thanks to @Bubu_Banini and @YaleFattyLiver for the support, as always.
📄 Full paper: mdpi.com/2673-4389/6/4/81
Gas-X Recall; MASLD and Alzheimer's Mortality; Counties Without a Gastroenterologist medpagetoday.com/gastroenter…
@AASLDtweets
43
Happy to share our 30-year national cohort study: non-obese patients with MASLD had over a threefold higher risk of Alzheimer’s disease–associated mortality than those with obesity. Grateful for the mentorship, our team, and the opportunity to keep learning about liver disease!
@AmerGastroAssn
@AASLDtweets
@AASLDFoundation
@AmCollegeGastro
@SarpB44
@basilenjei
#GITweet
ghadvances.org/article/S2772…
Mapouka Mexan MD, MPH retweeted
Increased Risk of Alzheimer Disease-Associated Mortality in Nonobese vs Obese Metabolic Dysfunction-Associated Steatotic Liver Disease: A 30-Year National Cohort Study - PubMed pubmed.ncbi.nlm.nih.gov/4243…
Mapouka Mexan MD, MPH retweeted
❌ NO significant difference in #MASH, #CardiovascularDisease or mortality between lean and non-lean patients with #MASLD.
Don’t be blinded by #obesity -- lean MASLD patients might be slipping under the radar 🫣
@MapoukaMexan @UMCapitalRegion #ACG2025
bit.ly/4oKnUyk
Happy to share our newly published retrospective cohort study, in which we examined national trends in chronic pancreatitis hospitalizations across the United States over time!@SarpB44
#GITweet @AmerGastroAssn @AmCollegeGastro
#Pancreatitis #Pancreas
Mapouka Mexan MD, MPH retweeted
Thank you, @AAFG_2021
We need to incorporate value-based care in MASH therapeutics
@DDWMeeting @basilenjei
#medtwitter #gitwitter
How does a resident get a full room to watch them present oral abstract lectures at large GI conferences?
Our ⭐ resident @SarpB44 sure knows how.
Top presentation on cost effectiveness of Resmetirom vs Semaglutide for non-cirrhotic MASH
#GItwitter





















